Cardiac-specific downregulation of KLF5 relieves myocardial ischemia/reperfusion injury by restoring autophagic flux

  • Eur J Pharmacol. 2026 Apr 28:1022:178832. doi: 10.1016/j.ejphar.2026.178832.
Huaqiang Mo  1 Haiqiong Liu  2 Wen Ou  3 Zhi Zeng  4 Hua Xiao  5 Chaobo Yang  4 Jing Yan  5 Weizhe Lu  5 Yuanna Ling  6 Yan Zhu  2 Xudong Song  7 Aihua Chen  8 Xianbao Wang  9
Affiliations
  • 1. Department of Cardiology, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University, Shenzhen, 518020, China.
  • 2. Department of Health Management, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou, 510280, China.
  • 3. Department of Cardiology, The Seventh Affiliated Hospital of Southern Medical University, Guangdong, Foshan, 528000, China.
  • 4. Department of Cardiovascular Medicine, ZhuJiang Hospital, Southern Medical University, Guangdong, Guangzhou, 510280, China.
  • 5. Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou, 510280, China.
  • 6. Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou, 510280, China.
  • 7. Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou, 510280, China. Electronic address: [email protected].
  • 8. Department of Health Management, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou, 510280, China. Electronic address: [email protected].
  • 9. Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou, 510280, China. Electronic address: [email protected].
Abstract

Krüppel-like factor 5 (KLF5) plays a critical role in various cardiovascular diseases. Previous studies have shown that KLF5 promotes oxidative stress and Apoptosis, thereby exacerbating myocardial remodeling. However, its specific role in myocardial ischemia/reperfusion (I/R) injury remains poorly understood. In this study, we investigated the effects of KLF5 in cardiomyocytes using both in vivo and in vitro models of myocardial I/R injury. Mice were subjected to myocardial I/R, and neonatal rat cardiomyocytes (NRCs) were treated with hypoxia/reoxygenation (H/R). We observed that KLF5 expression was significantly upregulated in the hearts of I/R mice and in H/R-treated cardiomyocytes during the early phase. Cardiac-specific knockdown of KLF5 attenuated myocardial injury in I/R mice, reduced Apoptosis, and decreased Reactive Oxygen Species (ROS) production in H/R-treated cardiomyocytes. Similar protective effects were observed following administration of a KLF5 inhibitor ML264. Notably, autophagic flux was impaired during I/R, whereas cardiac-specific KLF5 downregulation restored autophagic flux in I/R mice. Mechanistically, KLF5 knockdown reduced myocardial infarct size and improved cardiac function in vivo by restoring autophagic flux, and these effects were abolished by treatment with Bafilomycin A1 (Baf). Furthermore, cardiac-specific KLF5 downregulation alleviated mitochondrial damage, inhibited cardiomyocyte Apoptosis in I/R mice, and reduced ROS accumulation in NRCs exposed to H/R through restoration of autophagic flux. In conclusion, our findings demonstrate that cardiac-specific downregulation of KLF5 protects against myocardial I/R injury by restoring autophagic flux, thereby suppressing Apoptosis and facilitating the clearance of damaged mitochondria. These results highlight KLF5 as a potential therapeutic target for mitigating myocardial ischemia/reperfusion injury.

Keywords
Apoptosis; Autophagic flux; Ischemia/reperfusion injury; KLF5; Mitochondrial damage.
Products